dbACP: A Comprehensive Database of Anti-Cancer Peptides

440 result(s) have been found!

Accession Name Sequence Source/Organism Mechanism Assay Type Cell Line Cancer Type Activity
dbacp06651 LUNA18 Not Available Synthetic Not available CellTiter-Glo Cell Viability assay NCI-H2122 NSCLC IC50 = 1.4 ± 0.3 nmol/L
dbacp06652 LUNA18 Not Available Synthetic Not available CellTiter-Glo Cell Viability assay MiaPaCa.2 Pancreatic Cancer IC50 = 1.4 ± 0.2 nmol/L
dbacp06653 LUNA18 Not Available Synthetic Not available CellTiter-Glo Cell Viability assay NCI-H441 NSCLC IC50 = 2.9 ± 0.7 nmol/L
dbacp06654 LUNA18 Not Available Synthetic Not available CellTiter-Glo Cell Viability assay LS 180 Colon Cancer IC50 = 2.7 ± 0.4 nmol/L
dbacp06655 LUNA18 Not Available Synthetic Not available CellTiter-Glo Cell Viability assay GSU Stomach Cancer IC50 = 0.17 ± 0.02 nmol/L
dbacp06669 Crabrolin FLPLILRKIVTAL European hornet (Vespa crabro) Not available MTT assay H-838 Lung Cancer IC50 = 27.71 μM
dbacp06670 Crabrolin FLPLILRKIVTAL European hornet (Vespa crabro) Not available MTT assay PC-3 Prostate Cancer IC50 = 32.13 μM
dbacp06671 Crabrolin FLPLILRKIVTAL European hornet (Vespa crabro) Not available MTT assay U-251-MG Brain Tumor IC50 = 20.13 μM
dbacp06672 Crabrolin FLPLILRKIVTAL European hornet (Vespa crabro) Not available MTT assay HCT-116 Colon Cancer IC50 = 8.539 μM
dbacp06673 Crabrolin FLPLILRKIVTAL European hornet (Vespa crabro) Not available MTT assay MCF-7 Breast Cancer IC50 = 26.49 μM
dbacp06674 Crabrolin-4R FLPRILRKIVTAL Synthetic Analog of Crabrolin Not available MTT assay H-838 Lung Cancer IC50 = 11.40 μM
dbacp06675 Crabrolin-4R FLPRILRKIVTAL Synthetic Analog of Crabrolin Not available MTT assay PC-3 Prostate Cancer IC50 = 17.98 μM
dbacp06676 Crabrolin-4R FLPRILRKIVTAL Synthetic Analog of Crabrolin Not available MTT assay U-251-MG Brain Tumor IC50 = 25.09 μM
dbacp06677 Crabrolin-4R FLPRILRKIVTAL Synthetic Analog of Crabrolin Not available MTT assay HCT-116 Colon Cancer IC50 = 47.02 μM
dbacp06678 Crabrolin-4R FLPRILRKIVTAL Synthetic Analog of Crabrolin Not available MTT assay MCF-7 Breast Cancer IC50 = 20.26 μM
dbacp06679 Crabrolin-4K FLPKILRKIVTAL Synthetic Analog of Crabrolin Not available MTT assay H-838 Lung Cancer IC50 = 22.55 μM
dbacp06680 Crabrolin-4K FLPKILRKIVTAL Synthetic Analog of Crabrolin Not available MTT assay PC-3 Prostate Cancer IC50 = 20.58 μM
dbacp06681 Crabrolin-4K FLPKILRKIVTAL Synthetic Analog of Crabrolin Not available MTT assay U-251-MG Brain Tumor IC50 = 23.51 μM
dbacp06682 Crabrolin-4K FLPKILRKIVTAL Synthetic Analog of Crabrolin Not available MTT assay HCT-116 Colon Cancer IC50 = 42.88 μM
dbacp06683 Crabrolin-4K FLPKILRKIVTAL Synthetic Analog of Crabrolin Not available MTT assay MCF-7 Breast Cancer IC50 = 23.18 μM
dbacp06684 Crabrolin-TR FLPRILRKIVRAL Synthetic Analog of Crabrolin Not available MTT assay H-838 Lung Cancer IC50 = 4.637 μM
dbacp06685 Crabrolin-TR FLPRILRKIVRAL Synthetic Analog of Crabrolin Not available MTT assay PC-3 Prostate Cancer IC50 = 3.944 μM
dbacp06686 Crabrolin-TR FLPRILRKIVRAL Synthetic Analog of Crabrolin Not available MTT assay U-251-MG Brain Tumor IC50 = 12.40 μM
dbacp06687 Crabrolin-TR FLPRILRKIVRAL Synthetic Analog of Crabrolin Not available MTT assay HCT-116 Colon Cancer IC50 = 2.810 μM
dbacp06688 Crabrolin-TR FLPRILRKIVRAL Synthetic Analog of Crabrolin Not available MTT assay MCF-7 Breast Cancer IC50 = 3.459 μM
dbacp06689 Crabrolin-FR RLPRILRKIVRAL Synthetic Analog of Crabrolin Not available MTT assay H-838 Lung Cancer IC50 = 31.51 μM
dbacp06690 Crabrolin-FR RLPRILRKIVRAL Synthetic Analog of Crabrolin Not available MTT assay PC-3 Prostate Cancer IC50 = 15.87 μM
dbacp06691 Crabrolin-FR RLPRILRKIVRAL Synthetic Analog of Crabrolin Not available MTT assay U-251-MG Brain Tumor IC50 = 62.17 μM
dbacp06692 Crabrolin-FR RLPRILRKIVRAL Synthetic Analog of Crabrolin Not available MTT assay HCT-116 Colon Cancer IC50 = 30.29 μM
dbacp06693 Crabrolin-FR RLPRILRKIVRAL Synthetic Analog of Crabrolin Not available MTT assay MCF-7 Breast Cancer IC50 = 33.85 μM
dbacp06694 Crabrolin-AR RLPRILRKIVRRL Synthetic Analog of Crabrolin Not available MTT assay H-838 Lung Cancer IC50 = 41.31 μM
dbacp06695 Crabrolin-AR RLPRILRKIVRRL Synthetic Analog of Crabrolin Not available MTT assay PC-3 Prostate Cancer IC50 = 28.78 μM
dbacp06696 Crabrolin-AR RLPRILRKIVRRL Synthetic Analog of Crabrolin Not available MTT assay U-251-MG Brain Tumor IC50 = 52.01 μM
dbacp06697 Crabrolin-AR RLPRILRKIVRRL Synthetic Analog of Crabrolin Not available MTT assay HCT-116 Colon Cancer IC50 = 29.90 μM
dbacp06698 Crabrolin-AR RLPRILRKIVRRL Synthetic Analog of Crabrolin Not available MTT assay MCF-7 Breast Cancer IC50 = 32.51 μM
dbacp06699 Crabrolin-PR RLRRILRKIVRRL Synthetic Analog of Crabrolin Not available MTT assay H-838 Lung Cancer IC50 = 32.32 μM
dbacp06700 Crabrolin-PR RLRRILRKIVRRL Synthetic Analog of Crabrolin Not available MTT assay PC-3 Prostate Cancer IC50 = 22.37 μM
dbacp06701 Crabrolin-PR RLRRILRKIVRRL Synthetic Analog of Crabrolin Not available MTT assay U-251-MG Brain Tumor IC50 = 17.70 μM
dbacp06702 Crabrolin-PR RLRRILRKIVRRL Synthetic Analog of Crabrolin Not available MTT assay HCT-116 Colon Cancer IC50 = 16.29 μM
dbacp06703 Crabrolin-PR RLRRILRKIVRRL Synthetic Analog of Crabrolin Not available MTT assay MCF-7 Breast Cancer IC50 = 12.29 μM
dbacp06722 GE18 GAGIVVASIDTGVRVSHE Aphanomyces invadans Not available MTT assay MCF-7 Breast Cancer IC50 = 35.34 µM
dbacp06776 MP1-Q12K IDWKKLLDAAKLIL Analog of Polybia MP1 Not available MTT assay A-549 Lung Cancer IC50 = 12.5 μM
dbacp06777 BK-1 rRP-Hyp-G-Thi-S-Apc-Thi-R Synthetic analogue of Bradykinin Not available MTS assay HCT-116 Colorectal Cancer Not Available
dbacp06778 BK-2 rRP-Hyp-G-Thi-S-f-Apc-R Synthetic analogue of Bradykinin Not available MTS assay HCT-116 Colorectal Cancer Not Available
dbacp06779 BK-3 Aaa-rRP-Hyp-G-Thi-S-Acc-Thi-R Synthetic analogue of Bradykinin Not available MTS assay HCT-116 Colorectal Cancer Not Available
dbacp06780 BK-4 Aaa-rRP-Hyp-G-Thi-S-f-Acc-R Synthetic analogue of Bradykinin Not available MTS assay HCT-116 Colorectal Cancer Not Available
dbacp06781 BK-5 rRP-Hyp-G-Thi-S-f-(L)Pip-R Synthetic analogue of Bradykinin Not available MTS assay HCT-116 Colorectal Cancer Not Available
dbacp06782 BK-6 Aaa-rRP-Hyp-G-Thi-S-(D)Pip-(L)Pip-R Synthetic analogue of Bradykinin Not available MTS assay HCT-116 Colorectal Cancer Not Available
dbacp06783 BK-7 rRP-Hyp-G-Thi-S-(D)Pip-Thi-R Synthetic analogue of Bradykinin Not available MTS assay HCT-116 Colorectal Cancer Not Available
dbacp06784 BK-8 Aaa-rRP-Hyp-G-Thi-S-(D)Pip-Thi-R Synthetic analogue of Bradykinin Not available MTS assay HCT-116 Colorectal Cancer Not Available
dbacp06785 NT-9 RRPYIL Synthetic analogue of Neurotensin Not available MTS assay HCT-116 Colorectal Cancer Not Available
dbacp06786 NT-10 RRPAIL Synthetic analogue of Neurotensin Not available MTS assay HCT-116 Colorectal Cancer Not Available
dbacp06787 NT-11 RRPYAL Synthetic analogue of Neurotensin Not available MTS assay HCT-116 Colorectal Cancer Not Available
dbacp06788 NT-12 PEGRKPY-Tle-L Synthetic analogue of Neurotensin Not available MTS assay HCT-116 Colorectal Cancer Not Available
dbacp06789 NT-12 PEGKRPY-Tle-L Synthetic analogue of Neurotensin Not available MTS assay HCT-116 Colorectal Cancer Not Available
dbacp06790 NT-12 PEGKKPY-Tle-L Synthetic analogue of Neurotensin Not available MTS assay HCT-116 Colorectal Cancer Not Available
dbacp06798 Test peptide YSFGL Neuropep Peptide Not available MTT assay A-549 Lung Cancer IC50 = 26.417±0.660 µM
dbacp06799 Test peptide YSFGL Neuropep Peptide Not available MTT assay MDA-MB-231 Lung Cancer IC50 = 39.047±0.770 µM
dbacp06842 Api8-NH2 UGLUGGLZGI Trichogin GA Not available MTS assay MDA-MB-231 Breast Cancer IC50 > 20 µM
dbacp06843 Leu4-NH2 UGLLGGLUGI Trichogin GA Not available MTS assay MDA-MB-231 Breast Cancer IC50 > 20 µM
dbacp06844 K2569-Lol UKLUKKLUKI Trichogin GA Not available MTS assay MDA-MB-231 Breast Cancer IC50 = 12 µM
dbacp06845 K259-NH2 UKLUKGLUKI Trichogin GA Not available MTS assay MDA-MB-231 Breast Cancer IC50 =13 µM
dbacp06846 K259-Lol UKLUKGLUKI Trichogin GA Not available MTS assay MDA-MB-231 Breast Cancer IC50 =10 µM
dbacp06847 K25-Lol UKLUKGLUGI Trichogin GA Not available MTS assay MDA-MB-231 Breast Cancer IC50 =9 µM
dbacp06848 K56-Lol UGLUKKLUGI Trichogin GA Not available MTS assay MDA-MB-231 Breast Cancer IC50 =12 µM
dbacp06849 K6-NH2 UGLUGKLUGI Trichogin GA Not available MTS assay MDA-MB-231 Breast Cancer IC50 =8 µM
dbacp06850 K2-NH2 UKLUGGLUGI Trichogin GA Not available MTS assay MDA-MB-231 Breast Cancer IC50 = 9 µM
dbacp06859 ALA-A2 KLWCKSSQVPQSR Alpha-Lactalbumin Not available MTT assay A-549 Lung Cancer ~50% cell viability
dbacp06860 ALA-A2 KLWCKSSQVPQSR Alpha-Lactalbumin Not available MTT assay HT-29 Colon Cancer ~50% cell viability
dbacp06865 Pep-1-Phor21 CGEMGWVRCKFAKFAKKFAKFAKKFAKFAK Hybrid peptide PEP1 and Phor 21 Not available AlamarBlue assay LNCaP Liver Cancer IC50 = 55.13 ± 13.56 µM
dbacp06866 Pep-1-Phor21 CGEMGWVRCKFAKFAKKFAKFAKKFAKFAK Hybrid peptide PEP1 and Phor 21 Not available AlamarBlue assay DU-145 Prostrate Cancer IC50 = 2.57 ± 2.02 µM
dbacp06867 Pep-1-Phor21 CGEMGWVRCKFAKFAKKFAKFAKKFAKFAK Hybrid peptide PEP1 and Phor 21 Not available AlamarBlue assay PC-3 Prostrate Cancer IC50 ≤ 0.6 μM
dbacp06921 Ocellatin-3N GIFDVLKNLAKGVITSLAS Leptodactylus nesiotus Not available CellTiter-Glo assay A-549 Lung Cancer LC50 = 35 ± 1 μM
dbacp06922 Ocellatin-3N GIFDVLKNLAKGVITSLAS Leptodactylus nesiotus Not available CellTiter-Glo assay MDA-MB-231 Breast Cancer LC50 = 51 ± 16 μM
dbacp06923 Ocellatin-3N GIFDVLKNLAKGVITSLAS Leptodactylus nesiotus Not available CellTiter-Glo assay HT-29 Colorectal Cancer LC50 = 69 ± 10 μM
dbacp06940 PS14 PTECQVGTTCKVES Aphanomyces invadans Not available LDH leakage assay Hep-2 Larynx Cancer 45.56 ± 2% LDH release at 20 µM
dbacp07012 Sansalvimide A LXVLF Fusarium sp. Not Available Not Available HCT-116 Colon Cancer IC50 = 9.8 µg/ml
dbacp07013 Sansalvimide A LXVLF Fusarium sp. Not Available Not Available Colo-205 Colon Cancer IC50 = 3.5 µg/ml
dbacp07014 Sansalvimide A LXVLF Fusarium sp. Not Available Not Available SK-MEL-2 Skin Cancer IC50 = 5.9 µg/ml
dbacp07258 trans-Phakellistatin 18 trans(P)PIPYPIF Synthetic Not Available MTT assay HepG-2 Liver Cancer IC50 = 67.5 ± 2.938 µM
dbacp07312 B1OS-L FLPLIASLAGNVVPKIFCKITKRC B-1OS Not Available MTT assay H-838 Lung Cancer IC50 = 3.976 µM
dbacp07313 B1OS-L FLPLIASLAGNVVPKIFCKITKRC B-1OS Not Available MTT assay PC-3 Prostate Cancer IC50 = 5.473 µM
dbacp07314 B1OS-L FLPLIASLAGNVVPKIFCKITKRC B-1OS Not Available MTT assay U251-MG Brain Tumor IC50 = 8.629 µM
dbacp07315 B1OS-L FLPLIASLAGNVVPKIFCKITKRC B-1OS Not Available MTT assay MCF-7 Breast Cancer IC50 = 8.883 µM
dbacp07316 B1OS-L FLPLIASLAGNVVPKIFCKITKRC B-1OS Not Available MTT assay HCT-116 Colon Cancer IC50 = 11.03 µM
dbacp07317 B1OS-D-L FlPLIASLAGNVVPKIFCKITKRC B-1OS Not Available MTT assay H-838 Lung Cancer IC50 = 2.553 µM
dbacp07318 B1OS-D-L FlPLIASLAGNVVPKIFCKITKRC B-1OS Not Available MTT assay PC-3 Prostate Cancer IC50 = 2.629 µM
dbacp07319 B1OS-D-L FlPLIASLAGNVVPKIFCKITKRC B-1OS Not Available MTT assay U251-MG Brain Tumor IC50 = 3.492 µM
dbacp07320 B1OS-D-L FlPLIASLAGNVVPKIFCKITKRC B-1OS Not Available MTT assay MCF-7 Breast Cancer IC50 = 3.17 µM
dbacp07321 B1OS-D-L FlPLIASLAGNVVPKIFCKITKRC B-1OS Not Available MTT assay HCT-116 Colon Cancer IC50 = 3.721 µM
dbacp07375 Brevinin-2DYd GIFDVVKGVLKGVGKNVAGSLLEQLKCKLSGGC Rana dybowskii Not Available MTT assay A-549 Lung Cancer IC50 = 2.975 µg/ml
dbacp07376 Brevinin-2DYd GIFDVVKGVLKGVGKNVAGSLLEQLKCKLSGGC Rana dybowskii Not Available MTT assay MCF-7 Breast Cancer IC50 = 25.74 µg/ml
dbacp07377 Brevinin-2DYd GIFDVVKGVLKGVGKNVAGSLLEQLKCKLSGGC Rana dybowskii Not Available MTT assay HeLa Cervical Cancer IC50 = 19.69 µg/ml
dbacp07378 Brevinin-2DYd GIFDVVKGVLKGVGKNVAGSLLEQLKCKLSGGC Rana dybowskii Not Available MTT assay LoVo Colon Cancer IC50 = 8.05 µg/ml
dbacp07379 Ranatuerin-2Lb GILSSIKGVAKGVAKNVAAQLLDTLKCKITGC Rana luteiventris Not Available MTT assay A-549 Lung Cancer IC50 = 15.32 µM
dbacp07380 Ranatuerin-2Lb GILSSIKGVAKGVAKNVAAQLLDTLKCKITGC Rana luteiventris Not Available MTT assay MCF-7 Breast Cancer IC50 = 45.25 µM
dbacp07381 Ranatuerin-2Lb GILSSIKGVAKGVAKNVAAQLLDTLKCKITGC Rana luteiventris Not Available MTT assay HeLa Cervical Cancer IC50 = 37.23 µM
dbacp07382 Ranatuerin-2Lb GILSSIKGVAKGVAKNVAAQLLDTLKCKITGC Rana luteiventris Not Available MTT assay LoVo Colon Cancer IC50 = 59.78 µM
dbacp07383 Odorranain-C1 GVLGAVKDLLIGAGKSAAQSVLKTLSCKLSNDC Odorrana grahami Not Available MTT assay A-549 Lung Cancer IC50 = 27.31 µM
dbacp07384 Odorranain-C1 GVLGAVKDLLIGAGKSAAQSVLKTLSCKLSNDC Odorrana grahami Not Available MTT assay MCF-7 Breast Cancer IC50 = 41.21 µM
dbacp07385 Odorranain-C1 GVLGAVKDLLIGAGKSAAQSVLKTLSCKLSNDC Odorrana grahami Not Available MTT assay HeLa Cervical Cancer IC50 = 52.83 µM
dbacp07386 Odorranain-C1 GVLGAVKDLLIGAGKSAAQSVLKTLSCKLSNDC Odorrana grahami Not Available MTT assay LoVo Colon Cancer IC50 = 55.22 µM
dbacp07387 Brevinin-2DYb GLFDVVKGVLKGAGKNVAGSLLEQLKCKLSGGC Rana dybowskii Not Available MTT assay A-549 Lung Cancer IC50 = 24.01 µM
dbacp07388 Brevinin-2DYb GLFDVVKGVLKGAGKNVAGSLLEQLKCKLSGGC Rana dybowskii Not Available MTT assay MCF-7 Breast Cancer IC50 = 37.84 µM
dbacp07389 Brevinin-2DYb GLFDVVKGVLKGAGKNVAGSLLEQLKCKLSGGC Rana dybowskii Not Available MTT assay HeLa Cervical Cancer IC50 = 23.26 µM
dbacp07390 Brevinin-2DYb GLFDVVKGVLKGAGKNVAGSLLEQLKCKLSGGC Rana dybowskii Not Available MTT assay LoVo Colon Cancer IC50 = 35.05 µM
dbacp07391 Ranatuerin-2 GLFLDTLKGAAKDVAGKLEGLKCKITGCKLP Rana catesbeiana Not Available MTT assay A-549 Lung Cancer IC50 > 128 µM
dbacp07392 Ranatuerin-2 GLFLDTLKGAAKDVAGKLEGLKCKITGCKLP Rana catesbeiana Not Available MTT assay MCF-7 Breast Cancer IC50 > 128 µM
dbacp07393 Ranatuerin-2 GLFLDTLKGAAKDVAGKLEGLKCKITGCKLP Rana catesbeiana Not Available MTT assay HeLa Cervical Cancer IC50 > 128 µM
dbacp07394 Ranatuerin-2 GLFLDTLKGAAKDVAGKLEGLKCKITGCKLP Rana catesbeiana Not Available MTT assay LoVo Colon Cancer IC50 = 128 µM
dbacp07509 cyclic dipeptide - 2b WA Synthetic Not Available MTT assay HeLa Cervical Cancer IC50 = 93.1 µM
dbacp07510 cyclic dipeptide - 2b WA Synthetic Not Available MTT assay MCF-7 Breast Cancer IC50 = 45.6 µM
dbacp07803 cT1 KWCFRVCYRGICYRRCRG Synthetic Not Available Resazurin dye assay MM96L Skin Cancer CC50 = 1.3 ± 0.1 µM
dbacp07804 cT1 KWCFRVCYRGICYRRCRG Synthetic Not Available Resazurin dye assay HT-144 Skin Cancer CC50 = 1.4 ± 0.1 µM
dbacp07805 cT1 KWCFRVCYRGICYRRCRG Synthetic Not Available Resazurin dye assay WM164 Skin Cancer CC50 = 2.7 ± 0.1 µM
dbacp07806 cT1 KWCFRVCYRGICYRRCRG Synthetic Not Available Resazurin dye assay MDA-MB-435S Skin Cancer CC50 = 2.7 ± 0.3 µM
dbacp07807 cT1 KWCFRVCYRGICYRRCRG Synthetic Not Available Resazurin dye assay K-562 Leukemia Cancer CC50 = 2.0 ± 0.1 µM
dbacp07808 cT1 KWCFRVCYRGICYRRCRG Synthetic Not Available Resazurin dye assay MCF-7 Breast Cancer CC50 = 6.4 ± 0.6 µM
dbacp07809 cT1 KWCFRVCYRGICYRRCRG Synthetic Not Available Resazurin dye assay HeLa Cervical Cancer CC50 = 6.7 ± 0.6 µM
dbacp07810 [R/K]cT1 KWCFKVCYKGICYKKCKG Synthetic Not Available Resazurin dye assay WM164 Skin Cancer CC50 = 4.3 ± 0.3 µM
dbacp07811 [R/K]cT1 KWCFKVCYKGICYKKCKG Synthetic Not Available Resazurin dye assay MDA-MB-435S Skin Cancer CC50 = 3.5 ± 0.4 µM
dbacp07812 [R/K]cT1 KWCFKVCYKGICYKKCKG Synthetic Not Available Resazurin dye assay K-562 Leukemia Cancer CC50 = 2.5 ± 0.1 µM
dbacp07813 [R/K]cT1 KWCFKVCYKGICYKKCKG Synthetic Not Available Resazurin dye assay HeLa Cervical Cancer CC50 = 13.4 ± 1.9 µM
dbacp07814 [W2S]cT1 KSCFRVCYRGICYRRCRG Synthetic Not Available Resazurin dye assay MM96L Skin Cancer CC50 = 2.0 ± 0.1 µM
dbacp07815 [W2S]cT1 KSCFRVCYRGICYRRCRG Synthetic Not Available Resazurin dye assay HT-144 Skin Cancer CC50 = 3.0 ± 0.2 µM
dbacp07816 [W2S]cT1 KSCFRVCYRGICYRRCRG Synthetic Not Available Resazurin dye assay WM164 Skin Cancer CC50 = 3.9 ± 0.2 µM
dbacp07817 [W2S]cT1 KSCFRVCYRGICYRRCRG Synthetic Not Available Resazurin dye assay MDA-MB-435S Skin Cancer CC50 = 18.9 ± 0.9 µM
dbacp07818 [W2S]cT1 KSCFRVCYRGICYRRCRG Synthetic Not Available Resazurin dye assay K-562 Leukemia Cancer CC50 = 2.7 ± 0.2 µM
dbacp07819 [W2S]cT1 KSCFRVCYRGICYRRCRG Synthetic Not Available Resazurin dye assay HeLa Cervical Cancer CC50 = 22.5 ± 2.1 µM
dbacp07820 [Y8S-I11S]cT1 KWCFRVCSRGSCYRRCRG Synthetic Not Available Resazurin dye assay MM96L Skin Cancer CC50 = 17.3 ± 1.0 µM
dbacp07821 [Y8S-I11S]cT1 KWCFRVCSRGSCYRRCRG Synthetic Not Available Resazurin dye assay HT-144 Skin Cancer CC50 = 27.8 ± 2.2 µM
dbacp07822 [Y8S-I11S]cT1 KWCFRVCSRGSCYRRCRG Synthetic Not Available Resazurin dye assay WM164 Skin Cancer CC50 = 28.2 ± 2.0 µM
dbacp07823 [Y8S-I11S]cT1 KWCFRVCSRGSCYRRCRG Synthetic Not Available Resazurin dye assay K-562 Leukemia Cancer CC50 = 13.2 ± 0.9 µM
dbacp07824 [R9S]cT1 KWCFRVCYSGICYRRCRG Synthetic Not Available Resazurin dye assay MDA-MB-435S Skin Cancer CC50 = 5.3 ± 0.6 µM
dbacp07825 [R14S]cT1 KWCFRVCYRGICYSRCRG Synthetic Not Available Resazurin dye assay MM96L Skin Cancer CC50 = 1.7 ± 0.1 µM
dbacp07826 [R14S]cT1 KWCFRVCYRGICYSRCRG Synthetic Not Available Resazurin dye assay HT-144 Skin Cancer CC50 = 2.3 ± 0.2 µM
dbacp07827 [R14S]cT1 KWCFRVCYRGICYSRCRG Synthetic Not Available Resazurin dye assay WM164 Skin Cancer CC50 = 2.7 ± 0.1 µM
dbacp07828 [R14S]cT1 KWCFRVCYRGICYSRCRG Synthetic Not Available Resazurin dye assay MDA-MB-435S Skin Cancer CC50 = 3.5 ± 0.3 µM
dbacp07829 [R14S]cT1 KWCFRVCYRGICYSRCRG Synthetic Not Available Resazurin dye assay HeLa Cervical Cancer CC50 = 7.5 ± 0.3 µM
dbacp07830 [R17S]cT1 KWCFRVCYRGICYRRCSG Synthetic Not Available Resazurin dye assay MM96L Skin Cancer CC50 = 1.8 ± 0.1 µM
dbacp07831 [R17S]cT1 KWCFRVCYRGICYRRCSG Synthetic Not Available Resazurin dye assay HT-144 Skin Cancer CC50 = 1.2 ± 0.1 µM
dbacp07832 [R17S]cT1 KWCFRVCYRGICYRRCSG Synthetic Not Available Resazurin dye assay WM164 Skin Cancer CC50 = 1.8 ± 0.1 µM
dbacp07833 [R17S]cT1 KWCFRVCYRGICYRRCSG Synthetic Not Available Resazurin dye assay MDA-MB-435S Skin Cancer CC50 = 4.5 ± 0.3 µM
dbacp07834 [R17S]cT1 KWCFRVCYRGICYRRCSG Synthetic Not Available Resazurin dye assay HeLa Cervical Cancer CC50 = 12.2 ± 0.4 µM
dbacp07835 [R9S-R14S-R17S]cT1 KWCFRVCYSGICYSRCSG Synthetic Not Available Resazurin dye assay HT-144 Skin Cancer CC50 = 11.8 ± 0.9 µM
dbacp07836 [R9S-R14S-R17S]cT1 KWCFRVCYSGICYSRCSG Synthetic Not Available Resazurin dye assay WM164 Skin Cancer CC50 = 11.1 ± 0.9 µM
dbacp07837 [R9S-R14S-R17S]cT1 KWCFRVCYSGICYSRCSG Synthetic Not Available Resazurin dye assay K-562 Leukemia Cancer CC50 = 4.8 ± 0.3 µM
dbacp07838 [G18K]cT1 KWCFRVCYRGICYRRCRK Synthetic Not Available Resazurin dye assay MM96L Skin Cancer CC50 = 1.0 ± 0.1 µM
dbacp07839 [G18K]cT1 KWCFRVCYRGICYRRCRK Synthetic Not Available Resazurin dye assay HT-144 Skin Cancer CC50 = 3.2 ± 0.1 µM
dbacp07840 [G18K]cT1 KWCFRVCYRGICYRRCRK Synthetic Not Available Resazurin dye assay WM164 Skin Cancer CC50 = 2.7 ± 0.2 µM
dbacp07841 [G18K]cT1 KWCFRVCYRGICYRRCRK Synthetic Not Available Resazurin dye assay K-562 Leukemia Cancer CC50 = 1.7 ± 0.1 µM
dbacp07842 [G18K]cT1 KWCFRVCYRGICYRRCRK Synthetic Not Available Resazurin dye assay HeLa Cervical Cancer CC50 = 6.7 ± 1.1 µM
dbacp07843 [I11F-G18K]cT1 KWCFRVCYRGFCYRRCRK Synthetic Not Available Resazurin dye assay MM96L Skin Cancer CC50 = 1.3 ± 0.1 µM
dbacp07844 [I11F-G18K]cT1 KWCFRVCYRGFCYRRCRK Synthetic Not Available Resazurin dye assay HT-144 Skin Cancer CC50 = 3.2 ± 0.1 µM
dbacp07845 [I11F-G18K]cT1 KWCFRVCYRGFCYRRCRK Synthetic Not Available Resazurin dye assay WM164 Skin Cancer CC50 = 2.9 ± 0.2 µM
dbacp07846 [I11F-G18K]cT1 KWCFRVCYRGFCYRRCRK Synthetic Not Available Resazurin dye assay K-562 Leukemia Cancer CC50 = 1.9 ± 0.1 µM
dbacp07847 [I11F-G18K]cT1 KWCFRVCYRGFCYRRCRK Synthetic Not Available Resazurin dye assay HeLa Cervical Cancer CC50 = 5.1 ± 0.3 µM
dbacp07882 0Dap GIKKWLHSAKKFGKKFVKKIZNS Synthetic Not Available WST-1 assay PANC-1 Pancreatic Cancer EC50 = 9.1±0.3 μM
dbacp07883 2Dap GIKXWLHSAKKFGXKFVKKIZNS Synthetic Not Available WST-1 assay PANC-1 Pancreatic Cancer EC50 = 14.7±0.6 μM
dbacp07884 4Dap GIKXWLHSAXKFGXKFVKXIZNS Synthetic Not Available WST-1 assay PANC-1 Pancreatic Cancer EC50 = 35.7±0.7 μM
dbacp07885 6Dap GIKXWLHSAXXFGXKFVXXIZNS Synthetic Not Available WST-1 assay PANC-1 Pancreatic Cancer EC50 = 55.0±1.8 μM
dbacp07886 8Dap GIXXWLHSAXXFGXXFVXXIZNS Synthetic Not Available WST-1 assay PANC-1 Pancreatic Cancer EC50 = 61.4±0.7 μM
dbacp08078 APETx4 GTTCYCGKTIGIYWFGKYSCPTNRGYTGSCPYFLGICCYPVD Anthopleura elegantissima Not Available CellTox Green Dye assay SH-SY5Y Brain Tumor Green object count = 400 /mm2 at 20 μM
dbacp08079 APETx4 GTTCYCGKTIGIYWFGKYSCPTNRGYTGSCPYFLGICCYPVD Anthopleura elegantissima Not Available CellTox Green Dye assay LNCaP Prostate Cancer Green object count = 300 /mm2 at 20 μM
dbacp08080 APETx4 GTTCYCGKTIGIYWFGKYSCPTNRGYTGSCPYFLGICCYPVD Anthopleura elegantissima Not Available CellTox Green Dye assay MDA-MB-435S Skin Cancer Green object count < 100 /mm2 at 20 μM
dbacp08087 PTP-7S EENFLGALFKALSKLL PTP-7 Not Available MTT assay HeLa Cervical Cancer 55 - 60% cell viability at 75 µM
dbacp08088 PTP-7S EENFLGALFKALSKLL PTP-7 Not Available MTT assay A-549 Lung Cancer 65% cell viability at 10 µΜ
dbacp08150 CIGB-552 HARIKpTFRRlKWKYKGKFW Synthetic Not Available Sulforhodamine B assay MCF-7 Breast Cancer IC50 = 379.1 ± 8.6 µM
dbacp08167 Bmattacin2 Not Available silkworm Bombyx mori Not Available MTS assay A-375 Skin Cancer IC50 = 5.23 μM
dbacp08168 Bmattacin2 Not Available silkworm Bombyx mori Not Available MTS assay HCT-116 Colorectal Cancer IC50 = 1.70 μM
dbacp08169 Peptide - 1 GF(A6c)G(A6c)KK(A6c)G(A6c)F(A6c)G(A6c)GKK(A6c)KKKK Synthetic Not Available CellTiter-Glo assay CPFAC-1 Pancreatic Cancer IC50 > 7.5 µM
dbacp08170 Peptide - 1 GF(A6c)G(A6c)KK(A6c)G(A6c)F(A6c)G(A6c)GKK(A6c)KKKK Synthetic Not Available CellTiter-Glo assay MCF-7 Breast Cancer IC50 = 6.2 µM
dbacp08171 Peptide - 1 GF(A6c)G(A6c)KK(A6c)G(A6c)F(A6c)G(A6c)GKK(A6c)KKKK Synthetic Not Available CellTiter-Glo assay IGROV-1 Ovarian Cancer IC50 > 7.5 µM
dbacp08172 Peptide - 1 GF(A6c)G(A6c)KK(A6c)G(A6c)F(A6c)G(A6c)GKK(A6c)KKKK Synthetic Not Available CellTiter-Glo assay COLO-205 Colon Cancer IC50 = 5.4 µM
dbacp08173 Peptide - 1 GF(A6c)G(A6c)KK(A6c)G(A6c)F(A6c)G(A6c)GKK(A6c)KKKK Synthetic Not Available CellTiter-Glo assay DLD-1 Colon Cancer IC50 > 7.5 µM
dbacp08174 Peptide - 1 GF(A6c)G(A6c)KK(A6c)G(A6c)F(A6c)G(A6c)GKK(A6c)KKKK Synthetic Not Available CellTiter-Glo assay UACC-62 Skin Cancer IC50 = 2.6 µM
dbacp08175 Peptide - 1 GF(A6c)G(A6c)KK(A6c)G(A6c)F(A6c)G(A6c)GKK(A6c)KKKK Synthetic Not Available CellTiter-Glo assay MiaPaCa.2 Pancreatic Cancer IC50 = 7.3 µM
dbacp08176 Peptide - 1 GF(A6c)G(A6c)KK(A6c)G(A6c)F(A6c)G(A6c)GKK(A6c)KKKK Synthetic Not Available CellTiter-Glo assay A-498 Renal Cancer IC50 = 3.0 µM
dbacp08177 Peptide - 1 GF(A6c)G(A6c)KK(A6c)G(A6c)F(A6c)G(A6c)GKK(A6c)KKKK Synthetic Not Available CellTiter-Glo assay PC-3 Prostate Cancer Not Available
dbacp08178 Peptide - 1 GF(A6c)G(A6c)KK(A6c)G(A6c)F(A6c)G(A6c)GKK(A6c)KKKK Synthetic Not Available CellTiter-Glo assay A-549 Lung Cancer Not Available
dbacp08179 Peptide - 1 GF(A6c)G(A6c)KK(A6c)G(A6c)F(A6c)G(A6c)GKK(A6c)KKKK Synthetic Not Available CellTiter-Glo assay NCI-H69 Lung Cancer Not Available
dbacp08180 Peptide - 1 GF(A6c)G(A6c)KK(A6c)G(A6c)F(A6c)G(A6c)GKK(A6c)KKKK Synthetic Not Available CellTiter-Glo assay RL Lymphoma Cancer Not Available
dbacp08181 Peptide - 2 GF(A6c)G(A6c)R(A6c)G(A6c)F(A6c)G(A6c)GR(A6c)RRRR Synthetic Not Available CellTiter-Glo assay CPFAC-1 Pancreatic Cancer IC50 = 2.6 µM
dbacp08182 Peptide - 2 GF(A6c)G(A6c)R(A6c)G(A6c)F(A6c)G(A6c)GR(A6c)RRRR Synthetic Not Available CellTiter-Glo assay MCF-7 Breast Cancer IC50 = 7.0 µM
dbacp08183 Peptide - 2 GF(A6c)G(A6c)R(A6c)G(A6c)F(A6c)G(A6c)GR(A6c)RRRR Synthetic Not Available CellTiter-Glo assay IGROV-1 Ovarian Cancer IC50 = 6.0 µM
dbacp08184 Peptide - 2 GF(A6c)G(A6c)R(A6c)G(A6c)F(A6c)G(A6c)GR(A6c)RRRR Synthetic Not Available CellTiter-Glo assay COLO-205 Colon Cancer IC50 = 6.6 µM
dbacp08185 Peptide - 2 GF(A6c)G(A6c)R(A6c)G(A6c)F(A6c)G(A6c)GR(A6c)RRRR Synthetic Not Available CellTiter-Glo assay DLD-1 Colon Cancer IC50 = 6.4 µM
dbacp08186 Peptide - 2 GF(A6c)G(A6c)R(A6c)G(A6c)F(A6c)G(A6c)GR(A6c)RRRR Synthetic Not Available CellTiter-Glo assay UACC-62 Skin Cancer IC50 = 6.4 µM
dbacp08187 Peptide - 2 GF(A6c)G(A6c)R(A6c)G(A6c)F(A6c)G(A6c)GR(A6c)RRRR Synthetic Not Available CellTiter-Glo assay MiaPaCa.2 Pancreatic Cancer IC50 = 5.0 µM
dbacp08188 Peptide - 2 GF(A6c)G(A6c)R(A6c)G(A6c)F(A6c)G(A6c)GR(A6c)RRRR Synthetic Not Available CellTiter-Glo assay A-498 Renal Cancer IC50 = 5.6 µM
dbacp08189 Peptide - 3 GF(A6c)G(A6c)Orn(A6c)G(A6c)F(A6c)G(A6c)GOrn(A6c)Orn-Orn- Orn- Orn Synthetic Not Available CellTiter-Glo assay CPFAC-1 Pancreatic Cancer IC50 = 5.9 µM
dbacp08190 Peptide - 3 GF(A6c)G(A6c)Orn(A6c)G(A6c)F(A6c)G(A6c)GOrn(A6c)Orn-Orn- Orn- Orn Synthetic Not Available CellTiter-Glo assay MCF-7 Breast Cancer IC50 = 4.6 µM
dbacp08191 Peptide - 3 GF(A6c)G(A6c)Orn(A6c)G(A6c)F(A6c)G(A6c)GOrn(A6c)Orn-Orn- Orn- Orn Synthetic Not Available CellTiter-Glo assay IGROV-1 Ovarian Cancer IC50 = 5.4 µM
dbacp08192 Peptide - 3 GF(A6c)G(A6c)Orn(A6c)G(A6c)F(A6c)G(A6c)GOrn(A6c)Orn-Orn- Orn- Orn Synthetic Not Available CellTiter-Glo assay COLO-205 Colon Cancer IC50 = 3.2 µM
dbacp08193 Peptide - 3 GF(A6c)G(A6c)Orn(A6c)G(A6c)F(A6c)G(A6c)GOrn(A6c)Orn-Orn- Orn- Orn Synthetic Not Available CellTiter-Glo assay DLD-1 Colon Cancer IC50 = 6.2 µM
dbacp08194 Peptide - 3 GF(A6c)G(A6c)Orn(A6c)G(A6c)F(A6c)G(A6c)GOrn(A6c)Orn-Orn- Orn- Orn Synthetic Not Available CellTiter-Glo assay UACC-62 Skin Cancer IC50 = 3.1 µM
dbacp08195 Peptide - 3 GF(A6c)G(A6c)Orn(A6c)G(A6c)F(A6c)G(A6c)GOrn(A6c)Orn-Orn- Orn- Orn Synthetic Not Available CellTiter-Glo assay MiaPaCa.2 Pancreatic Cancer IC50 = 3.6 µM
dbacp08196 Peptide - 3 GF(A6c)G(A6c)Orn(A6c)G(A6c)F(A6c)G(A6c)GOrn(A6c)Orn-Orn- Orn- Orn Synthetic Not Available CellTiter-Glo assay A-498 Renal Cancer IC50 = 4.7 µM
dbacp08197 Peptide - 4 GF(A6c)G(A6c)Dab(A6c)G(A6c)F(A6c)G(A6c)GDab(A6c)Dab-Dab-Dab-Dab Synthetic Not Available CellTiter-Glo assay CPFAC-1 Pancreatic Cancer IC50 = 2.7 µM
dbacp08198 Peptide - 4 GF(A6c)G(A6c)Dab(A6c)G(A6c)F(A6c)G(A6c)GDab(A6c)Dab-Dab-Dab-Dab Synthetic Not Available CellTiter-Glo assay MCF-7 Breast Cancer IC50 = 3.0 µM
dbacp08199 Peptide - 4 GF(A6c)G(A6c)Dab(A6c)G(A6c)F(A6c)G(A6c)GDab(A6c)Dab-Dab-Dab-Dab Synthetic Not Available CellTiter-Glo assay IGROV-1 Ovarian Cancer IC50 = 2.3 µM
dbacp08200 Peptide - 4 GF(A6c)G(A6c)Dab(A6c)G(A6c)F(A6c)G(A6c)GDab(A6c)Dab-Dab-Dab-Dab Synthetic Not Available CellTiter-Glo assay COLO-205 Colon Cancer IC50 = 6.4 µM
dbacp08201 Peptide - 4 GF(A6c)G(A6c)Dab(A6c)G(A6c)F(A6c)G(A6c)GDab(A6c)Dab-Dab-Dab-Dab Synthetic Not Available CellTiter-Glo assay DLD-1 Colon Cancer IC50 = 2.6 µM
dbacp08202 Peptide - 4 GF(A6c)G(A6c)Dab(A6c)G(A6c)F(A6c)G(A6c)GDab(A6c)Dab-Dab-Dab-Dab Synthetic Not Available CellTiter-Glo assay UACC-62 Skin Cancer IC50 = 1.9 µM
dbacp08203 Peptide - 4 GF(A6c)G(A6c)Dab(A6c)G(A6c)F(A6c)G(A6c)GDab(A6c)Dab-Dab-Dab-Dab Synthetic Not Available CellTiter-Glo assay MiaPaCa.2 Pancreatic Cancer IC50 = 4.4 µM
dbacp08204 Peptide - 4 GF(A6c)G(A6c)Dab(A6c)G(A6c)F(A6c)G(A6c)GDab(A6c)Dab-Dab-Dab-Dab Synthetic Not Available CellTiter-Glo assay A-498 Renal Cancer IC50 = 2.1 µM
dbacp08205 Peptide - 6 GF(A5c)G(A5c)K(A5c)G(A5c)F(A5c)G(A5c)GK(A5c)KKKK Synthetic Not Available CellTiter-Glo assay CPFAC-1 Pancreatic Cancer IC50 > 7.5 µM
dbacp08206 Peptide - 6 GF(A5c)G(A5c)K(A5c)G(A5c)F(A5c)G(A5c)GK(A5c)KKKK Synthetic Not Available CellTiter-Glo assay MCF-7 Breast Cancer IC50 > 7.5 µM
dbacp08207 Peptide - 6 GF(A5c)G(A5c)K(A5c)G(A5c)F(A5c)G(A5c)GK(A5c)KKKK Synthetic Not Available CellTiter-Glo assay IGROV-1 Ovarian Cancer IC50 > 7.5 µM
dbacp08208 Peptide - 6 GF(A5c)G(A5c)K(A5c)G(A5c)F(A5c)G(A5c)GK(A5c)KKKK Synthetic Not Available CellTiter-Glo assay COLO-205 Colon Cancer IC50 > 7.5 µM
dbacp08209 Peptide - 6 GF(A5c)G(A5c)K(A5c)G(A5c)F(A5c)G(A5c)GK(A5c)KKKK Synthetic Not Available CellTiter-Glo assay DLD-1 Colon Cancer IC50 > 7.5 µM
dbacp08210 Peptide - 6 GF(A5c)G(A5c)K(A5c)G(A5c)F(A5c)G(A5c)GK(A5c)KKKK Synthetic Not Available CellTiter-Glo assay UACC-62 Skin Cancer IC50 > 7.5 µM
dbacp08211 Peptide - 6 GF(A5c)G(A5c)K(A5c)G(A5c)F(A5c)G(A5c)GK(A5c)KKKK Synthetic Not Available CellTiter-Glo assay MiaPaCa.2 Pancreatic Cancer IC50 > 7.5 µM
dbacp08212 Peptide - 6 GF(A5c)G(A5c)K(A5c)G(A5c)F(A5c)G(A5c)GK(A5c)KKKK Synthetic Not Available CellTiter-Glo assay A-498 Renal Cancer IC50 > 7.5 µM
dbacp08213 Peptide - 7 GF(A5c)G(A5c)R(A5c)G(A5c)F(A5c)G(A5c)GR(A5c)RRRR Synthetic Not Available CellTiter-Glo assay CPFAC-1 Pancreatic Cancer IC50 > 7.5 µM
dbacp08214 Peptide - 7 GF(A5c)G(A5c)R(A5c)G(A5c)F(A5c)G(A5c)GR(A5c)RRRR Synthetic Not Available CellTiter-Glo assay MCF-7 Breast Cancer IC50 > 7.5 µM
dbacp08215 Peptide - 7 GF(A5c)G(A5c)R(A5c)G(A5c)F(A5c)G(A5c)GR(A5c)RRRR Synthetic Not Available CellTiter-Glo assay IGROV-1 Ovarian Cancer IC50 > 7.5 µM
dbacp08216 Peptide - 7 GF(A5c)G(A5c)R(A5c)G(A5c)F(A5c)G(A5c)GR(A5c)RRRR Synthetic Not Available CellTiter-Glo assay COLO-205 Colon Cancer IC50 > 7.5 µM
dbacp08217 Peptide - 7 GF(A5c)G(A5c)R(A5c)G(A5c)F(A5c)G(A5c)GR(A5c)RRRR Synthetic Not Available CellTiter-Glo assay DLD-1 Colon Cancer IC50 > 7.5 µM
dbacp08218 Peptide - 7 GF(A5c)G(A5c)R(A5c)G(A5c)F(A5c)G(A5c)GR(A5c)RRRR Synthetic Not Available CellTiter-Glo assay UACC-62 Skin Cancer IC50 > 7.5 µM
dbacp08219 Peptide - 7 GF(A5c)G(A5c)R(A5c)G(A5c)F(A5c)G(A5c)GR(A5c)RRRR Synthetic Not Available CellTiter-Glo assay MiaPaCa.2 Pancreatic Cancer IC50 > 7.5 µM
dbacp08220 Peptide - 7 GF(A5c)G(A5c)R(A5c)G(A5c)F(A5c)G(A5c)GR(A5c)RRRR Synthetic Not Available CellTiter-Glo assay A-498 Renal Cancer IC50 > 7.5 µM
dbacp08221 Peptide - 8 GF(A6c)G(Tic)K(A6c)G(Tic)F(A6c)G(Tic)GK(Tic)KKKK Synthetic Not Available CellTiter-Glo assay CPFAC-1 Pancreatic Cancer IC50 > 7.5 µM
dbacp08222 Peptide - 8 GF(A6c)G(Tic)K(A6c)G(Tic)F(A6c)G(Tic)GK(Tic)KKKK Synthetic Not Available CellTiter-Glo assay MCF-7 Breast Cancer IC50 > 7.5 µM
dbacp08223 Peptide - 8 GF(A6c)G(Tic)K(A6c)G(Tic)F(A6c)G(Tic)GK(Tic)KKKK Synthetic Not Available CellTiter-Glo assay IGROV-1 Ovarian Cancer IC50 > 7.5 µM
dbacp08224 Peptide - 8 GF(A6c)G(Tic)K(A6c)G(Tic)F(A6c)G(Tic)GK(Tic)KKKK Synthetic Not Available CellTiter-Glo assay COLO-205 Colon Cancer IC50 > 7.5 µM
dbacp08225 Peptide - 8 GF(A6c)G(Tic)K(A6c)G(Tic)F(A6c)G(Tic)GK(Tic)KKKK Synthetic Not Available CellTiter-Glo assay DLD-1 Colon Cancer IC50 > 7.5 µM
dbacp08226 Peptide - 8 GF(A6c)G(Tic)K(A6c)G(Tic)F(A6c)G(Tic)GK(Tic)KKKK Synthetic Not Available CellTiter-Glo assay UACC-62 Skin Cancer IC50 > 7.5 µM
dbacp08227 Peptide - 8 GF(A6c)G(Tic)K(A6c)G(Tic)F(A6c)G(Tic)GK(Tic)KKKK Synthetic Not Available CellTiter-Glo assay MiaPaCa.2 Pancreatic Cancer IC50 > 7.5 µM
dbacp08228 Peptide - 8 GF(A6c)G(Tic)K(A6c)G(Tic)F(A6c)G(Tic)GK(Tic)KKKK Synthetic Not Available CellTiter-Glo assay A-498 Renal Cancer IC50 > 7.5 µM
dbacp08229 Peptide - 9 GF(A6c)G(Oic)K(A6c)G(Oic)F(A6c)G(Oic)GK(Oic)KKKK Synthetic Not Available CellTiter-Glo assay CPFAC-1 Pancreatic Cancer IC50 > 7.5 µM
dbacp08230 Peptide - 9 GF(A6c)G(Oic)K(A6c)G(Oic)F(A6c)G(Oic)GK(Oic)KKKK Synthetic Not Available CellTiter-Glo assay MCF-7 Breast Cancer IC50 > 7.5 µM
dbacp08231 Peptide - 9 GF(A6c)G(Oic)K(A6c)G(Oic)F(A6c)G(Oic)GK(Oic)KKKK Synthetic Not Available CellTiter-Glo assay IGROV-1 Ovarian Cancer IC50 > 7.5 µM
dbacp08232 Peptide - 9 GF(A6c)G(Oic)K(A6c)G(Oic)F(A6c)G(Oic)GK(Oic)KKKK Synthetic Not Available CellTiter-Glo assay COLO-205 Colon Cancer IC50 > 7.5 µM
dbacp08233 Peptide - 9 GF(A6c)G(Oic)K(A6c)G(Oic)F(A6c)G(Oic)GK(Oic)KKKK Synthetic Not Available CellTiter-Glo assay DLD-1 Colon Cancer IC50 > 7.5 µM
dbacp08234 Peptide - 9 GF(A6c)G(Oic)K(A6c)G(Oic)F(A6c)G(Oic)GK(Oic)KKKK Synthetic Not Available CellTiter-Glo assay UACC-62 Skin Cancer IC50 > 7.5 µM
dbacp08235 Peptide - 9 GF(A6c)G(Oic)K(A6c)G(Oic)F(A6c)G(Oic)GK(Oic)KKKK Synthetic Not Available CellTiter-Glo assay MiaPaCa.2 Pancreatic Cancer IC50 > 7.5 µM
dbacp08236 Peptide - 9 GF(A6c)G(Oic)K(A6c)G(Oic)F(A6c)G(Oic)GK(Oic)KKKK Synthetic Not Available CellTiter-Glo assay A-498 Renal Cancer IC50 > 7.5 µM
dbacp08237 Peptide - 10 GF(A5c)G(A6c)K(A5c)G(A6c)F(A5c)G(A6c)GK(A5c)KKKK Synthetic Not Available CellTiter-Glo assay CPFAC-1 Pancreatic Cancer IC50 > 7.5 µM
dbacp08238 Peptide - 10 GF(A5c)G(A6c)K(A5c)G(A6c)F(A5c)G(A6c)GK(A5c)KKKK Synthetic Not Available CellTiter-Glo assay MCF-7 Breast Cancer IC50 > 7.5 µM
dbacp08239 Peptide - 10 GF(A5c)G(A6c)K(A5c)G(A6c)F(A5c)G(A6c)GK(A5c)KKKK Synthetic Not Available CellTiter-Glo assay IGROV-1 Ovarian Cancer IC50 > 7.5 µM
dbacp08240 Peptide - 10 GF(A5c)G(A6c)K(A5c)G(A6c)F(A5c)G(A6c)GK(A5c)KKKK Synthetic Not Available CellTiter-Glo assay COLO-205 Colon Cancer IC50 > 7.5 µM
dbacp08241 Peptide - 10 GF(A5c)G(A6c)K(A5c)G(A6c)F(A5c)G(A6c)GK(A5c)KKKK Synthetic Not Available CellTiter-Glo assay DLD-1 Colon Cancer IC50 > 7.5 µM
dbacp08242 Peptide - 10 GF(A5c)G(A6c)K(A5c)G(A6c)F(A5c)G(A6c)GK(A5c)KKKK Synthetic Not Available CellTiter-Glo assay UACC-62 Skin Cancer IC50 > 7.5 µM
dbacp08243 Peptide - 10 GF(A5c)G(A6c)K(A5c)G(A6c)F(A5c)G(A6c)GK(A5c)KKKK Synthetic Not Available CellTiter-Glo assay MiaPaCa.2 Pancreatic Cancer IC50 > 7.5 µM
dbacp08244 Peptide - 10 GF(A5c)G(A6c)K(A5c)G(A6c)F(A5c)G(A6c)GK(A5c)KKKK Synthetic Not Available CellTiter-Glo assay A-498 Renal Cancer IC50 > 7.5 µM
dbacp08245 Peptide - 11 KKKKGF(A6c)G(A6c)K(A6c)G(A6c)F(A6c)G(A6c)GK(A6c) Synthetic Not Available CellTiter-Glo assay CPFAC-1 Pancreatic Cancer IC50 > 7.5 µM
dbacp08246 Peptide - 11 KKKKGF(A6c)G(A6c)K(A6c)G(A6c)F(A6c)G(A6c)GK(A6c) Synthetic Not Available CellTiter-Glo assay MCF-7 Breast Cancer IC50 = 7.3 µM
dbacp08247 Peptide - 11 KKKKGF(A6c)G(A6c)K(A6c)G(A6c)F(A6c)G(A6c)GK(A6c) Synthetic Not Available CellTiter-Glo assay IGROV-1 Ovarian Cancer IC50 > 7.5 µM
dbacp08248 Peptide - 11 KKKKGF(A6c)G(A6c)K(A6c)G(A6c)F(A6c)G(A6c)GK(A6c) Synthetic Not Available CellTiter-Glo assay COLO-205 Colon Cancer IC50 = 6.7 µM
dbacp08249 Peptide - 11 KKKKGF(A6c)G(A6c)K(A6c)G(A6c)F(A6c)G(A6c)GK(A6c) Synthetic Not Available CellTiter-Glo assay DLD-1 Colon Cancer IC50 > 7.5 µM
dbacp08250 Peptide - 11 KKKKGF(A6c)G(A6c)K(A6c)G(A6c)F(A6c)G(A6c)GK(A6c) Synthetic Not Available CellTiter-Glo assay UACC-62 Skin Cancer IC50 = 6.4 µM
dbacp08251 Peptide - 11 KKKKGF(A6c)G(A6c)K(A6c)G(A6c)F(A6c)G(A6c)GK(A6c) Synthetic Not Available CellTiter-Glo assay MiaPaCa.2 Pancreatic Cancer IC50 > 7.5 µM
dbacp08252 Peptide - 11 KKKKGF(A6c)G(A6c)K(A6c)G(A6c)F(A6c)G(A6c)GK(A6c) Synthetic Not Available CellTiter-Glo assay A-498 Renal Cancer IC50 = 4.2 µM
dbacp08254 Tr1 Not Available Protein extraction from Spirulina platensis Not Available MTT assay MCF-7 Breast Cancer IC50 = 60.12 μg/mL
dbacp08255 Tr1 Not Available Protein extraction from Spirulina platensis Not Available MTT assay HepG-2 Liver Cancer IC50 = 147.03 μg/mL
dbacp08256 Tr2 Not Available Protein extraction from Spirulina platensis Not Available MTT assay MCF-7 Breast Cancer IC50 < 31.25 μg/mL
dbacp08257 Tr2 Not Available Protein extraction from Spirulina platensis Not Available MTT assay HepG-2 Liver Cancer IC50 = 36.42 μg/mL
dbacp08258 Tr2 Not Available Protein extraction from Spirulina platensis Not Available MTT assay SGC-7901 Gastric Cancer IC50 = 48.25 μg/mL
dbacp08259 Tr3 Not Available Protein extraction from Spirulina platensis Not Available MTT assay HT-29 Colon Cancer IC50 = 112.89 μg/mL
dbacp08260 Tr4 Not Available Protein extraction from Spirulina platensis Not Available MTT assay MCF-7 Breast Cancer IC50 = 238.86 μg/mL
dbacp08261 Tr4 Not Available Protein extraction from Spirulina platensis Not Available MTT assay HepG-2 Liver Cancer IC50 = 176.37 μg/mL
dbacp08262 HR HVLSRAPR Fraction identified from Tr1 Not Available MTT assay HT-29 Colon Cancer IC50 = 99.88 μg/mL
dbacp08263 HR HVLSRAPR Fraction identified from Tr1 Not Available MTT assay HepG-2 Liver Cancer 22% inhibition at 500 μg/mL
dbacp08264 HR HVLSRAPR Fraction identified from Tr1 Not Available MTT assay SGC-7901 Gastric Cancer 20% inhibition at 500 μg/mL
dbacp08265 HR HVLSRAPR Fraction identified from Tr1 Not Available MTT assay A-549 Lung Cancer 15% inhibition at 500 μg/mL
dbacp08266 ZXR-2 FKIGGFIKKLWRSLLA Synthetic Not Available MTT assay HeLa Cervical Cancer IC50 = 8.1 ± 1.6 μM
dbacp08267 ZXR-2 FKIGGFIKKLWRSLLA Synthetic Not Available MTT assay SACC-83 Salivary Cancer IC50 = 9.9 ± 1.7 μM
dbacp08268 ZXR-2 FKIGGFIKKLWRSLLA Synthetic Not Available MTT assay HepG-2 Liver Cancer IC50 = 7.5 ± 1.2 μM
dbacp08269 ZXR-2 FKIGGFIKKLWRSLLA Synthetic Not Available MTT assay Huh-7 Liver Cancer IC50 = 8.4 ± 1.1 μM
dbacp08270 ZXR-2 FKIGGFIKKLWRSLLA Synthetic Not Available MTT assay PC-3 Prostate Cancer IC50 = 14.2 ± 0.5 μM
dbacp08271 ZXR-2 FKIGGFIKKLWRSLLA Synthetic Not Available MTT assay 293T Kidney Cancer IC50 = 6.3 ± 0.7 μM
dbacp08272 [Lys5,6] TG UGLUKKLUGI Trichogin GA Not Available MTT assay T-67 Brain Tumor EC50 = 7 µM
dbacp08273 [Lys5,6] TG UGLUKKLUGI Trichogin GA Not Available MTT assay HeLa Cervical Cancer EC50 = 10 µM
dbacp08274 [Lys6] TG UGLUGKLUGI Trichogin GA Not Available MTT assay T-67 Brain Tumor EC50 = 4 µM
dbacp08275 [Lys6] TG UGLUGKLUGI Trichogin GA Not Available MTT assay HeLa Cervical Cancer EC50 = 2 µM
dbacp08276 Trichogin GA UGLUGGLUGI Trichoderma longibrachiatum Not Available MTT assay T-67 Brain Tumor EC50 = 2 µM
dbacp08277 Trichogin GA UGLUGGLUGI Trichoderma longibrachiatum Not Available MTT assay HeLa Cervical Cancer EC50 = 8 µM
dbacp08278 [TOAC1] TG XGLUGGLUGI Trichogin GA Not Available MTT assay T-67 Brain Tumor EC50 = 1 µM
dbacp08279 [TOAC1] TG XGLUGGLUGI Trichogin GA Not Available MTT assay HeLa Cervical Cancer EC50 = 3 µM
dbacp08280 [TOAC1, Lys6] TG XGLUGKLUGI Trichogin GA Not Available MTT assay T-67 Brain Tumor EC50 = 1 µM
dbacp08281 [TOAC1, Lys6] TG XGLUGKLUGI Trichogin GA Not Available MTT assay HeLa Cervical Cancer EC50 = 3 µM
dbacp08282 [Arg2] TG URLUGGLUGI Trichogin GA Not Available MTT assay T-67 Brain Tumor EC50 = 8 µM
dbacp08283 [Arg2] TG URLUGGLUGI Trichogin GA Not Available MTT assay HeLa Cervical Cancer EC50 = 4 µM
dbacp08284 [TOAC1, Arg2] TG XRLUGGLUGI Trichogin GA Not Available MTT assay T-67 Brain Tumor EC50 = 8 µM
dbacp08285 [TOAC1, Arg2] TG XRLUGGLUGI Trichogin GA Not Available MTT assay HeLa Cervical Cancer EC50 = 9 µM
dbacp08286 [TOAC1, Arg9] TG XGLUGGLURI Trichogin GA Not Available MTT assay T-67 Brain Tumor EC50 = 8 µM
dbacp08287 [TOAC1, Arg9] TG XGLUGGLURI Trichogin GA Not Available MTT assay HeLa Cervical Cancer EC50 = 5 µM
dbacp08288 [TOAC1, Lys5,6] TG XGLUKKLUGI Trichogin GA Not Available MTT assay T-67 Brain Tumor EC50 = 10 µM
dbacp08289 [TOAC1, Lys5,6] TG XGLUKKLUGI Trichogin GA Not Available MTT assay HeLa Cervical Cancer EC50 = 6 µM
dbacp08290 [TOAC1, Api4] TG XGLZGGLUGI Trichogin GA Not Available MTT assay T-67 Brain Tumor EC50 = 13 µM
dbacp08291 L-Carnosine Beta-AH Synthetic Not Available MTT assay A-2780 Ovarian Cancer IC50 = 165 mM
dbacp08292 L-Carnosine Beta-AH Synthetic Not Available MTT assay OVCAR-3 Ovarian Cancer IC50 = 125 mM
dbacp08293 L-Carnosine Beta-AH Synthetic Not Available MTT assay SK-OV-3 Ovarian Cancer IC50 = 485 mM
dbacp08294 CA4 CGPCFTTDHNMARKCDECCGGKGRGKCFGPQCLCR Synthetic Not Available MTT assay U-251 Brain Tumor Graph Figure 2
dbacp08295 CTX-23 VCMPCFTTDQQMARKCSDCCGGKGRGKCYGPQCLCR Synthetic Not Available MTT assay U-251 Brain Tumor Graph Figure 2
dbacp08296 BnSP-6 SLFELGKMILQETGKNPAKSYGAYGCNCGVLGRGGPKDATDRCCYVHKCCYKKLTGCDPKKDRYSYSWKDKTIVCGENNPCLKELCECDKAVAICLRENLGTYNKKYRYHLKPFCKKADPC B. pauloensis Not Available MTT assay MDA-MB-231 Breast Cancer 45% cell cytotoxicity at 100 μg/mL
dbacp08297 DN1 ILGKIVKKLVSDF Synthetic Not Available MTT assay HepG-2 Liver Cancer 152.17 ± 7.73 μM
dbacp08298 DN4 ILGKIWKGIVSDF Synthetic Not Available MTT assay HepG-2 Liver Cancer 191.67 ± 12.02 μM
dbacp08299 SKACP003 FPLPCAYKGTYC Synthetic Not Available MTT assay MCF-7 Breast Cancer IC50 = 193 ± 0.5 µM
dbacp08300 SKACP003 FPLPCAYKGTYC Synthetic Not Available MTT assay MDA-MB-231 Breast Cancer IC50 = 212 ± 0.5 µM
dbacp08301 SKACP003 FPLPCAYKGTYC Synthetic Not Available MTT assay MDA-MB-453 Breast Cancer IC50 = 156 ± 0.5 µM
dbacp08302 RF13 RRGKGGRRVTMSF VSP26B of C. striatus Not Available MTT assay HEp-2 Larynx Cancer IC50 = 49.65 µM
dbacp08303 ATRA1-R3W2 - HYD RRWKRFFKRWKGGVIGVTFPF Synthetic Not Available Cytotoxicity assay H-358 Lung Cancer LD50 ~24.5 μM
dbacp08304 MAD1 KRWHWWRRHWVVW Synthetic Not Available MTT assay OVCAR-3 Ovarian Cancer IC50 = 14.2 μM
dbacp08305 MAD1 KRWHWWRRHWVVW Synthetic Not Available MTT assay A-549 Lung Cancer IC50 = 36.2 μM
dbacp08306 MAD1 KRWHWWRRHWVVW Synthetic Not Available MTT assay NCI/ADR-RES Ovarian Cancer IC50 = 85.6 μM
dbacp08307 DAP1 LWKRWVGVWRKWL Synthetic Not Available MTT assay A-549 Lung Cancer IC50 = 11.9 μM
dbacp08308 DAP1 LWKRWVGVWRKWL Synthetic Not Available MTT assay OVCAR-3 Ovarian Cancer IC50 = 8.6 μM
dbacp08309 DAP1 LWKRWVGVWRKWL Synthetic Not Available MTT assay NCI/ADR-RES Ovarian Cancer IC50 = 14.0 μM
dbacp08310 DAP1 LWKRWVGVWRKWL Synthetic Not Available MTT assay T-24 Bladder Cancer IC50 = 15.3 μM
dbacp08311 AMP1 WKWLKKWIK Synthetic Not Available MTT assay OVCAR-3 Ovarian Cancer IC50 = 51.1 μM
dbacp08312 AMP2 KRWWKWWRR Synthetic Not Available MTT assay OVCAR-3 Ovarian Cancer IC50 = 53.5 μM
dbacp08313 P1C YKSIEFC Synthetic Not Available Cell Proliferation assay BXPC-3 Pancreatic Cancer ~40% reduction in cell growth at 20 μM
dbacp08314 P1A YKSIEFC Synthetic Not Available Cell Proliferation assay BXPC-4 Pancreatic Cancer ~50% reduction in cell growth at 20 μM
dbacp08315 P1B YKSVEFC Synthetic Not Available Cell Proliferation assay BXPC-5 Pancreatic Cancer ~50% reduction in cell growth at 20 μM
dbacp08316 Sample Peptide 1 from US011339203B2 LTSVVFILICCFHLENIFVLLKKRTLRKNDRKKR Synthetic Not Available CCK-8 assay CAKI-2 Renal Cancer Cell Viability = 48% at 25 μM
dbacp08317 Sample Peptide 2 from US011339203B2 FIGNLALSDLLAGVAYTANLLLKKRTLRKNDRKKR Synthetic Not Available CCK-8 assay CAKI-2 Renal Cancer Cell Viability = 0.4% at 25 μM
dbacp08318 Sample Peptide 2 from US011339203B2 FIGNLALSDLLAGVAYTANLLLKKRTLRKNDRKKR Synthetic Not Available CCK-8 assay PC-3 Prostate Cancer Cell Viability = 2.5% at 25 μM
dbacp08319 Sample Peptide 2 from US011339203B2 FIGNLALSDLLAGVAYTANLLLKKRTLRKNDRKKR Synthetic Not Available CCK-8 assay A-2058 Skin Cancer Cell Viability = 0.2% at 25 μM
dbacp08320 Sample Peptide 2 from US011339203B2 FIGNLALSDLLAGVAYTANLLLKKRTLRKNDRKKR Synthetic Not Available CCK-8 assay NCI-H2444 Lung Cancer Cell Viability = 0.6% at 25 μM
dbacp08321 Sample Peptide 2 from US011339203B2 FIGNLALSDLLAGVAYTANLLLKKRTLRKNDRKKR Synthetic Not Available CCK-8 assay A-549 Lung Cancer Cell Viability = 1.4% at 25 μM
dbacp08322 Sample Peptide 3 from US011339203B2 WFLREGSMFVALSASVFSLLAIKKRTLRKNDRKKR Synthetic Not Available CCK-8 assay CAKI-2 Renal Cancer Cell Viability = 45.8% at 25 μM
dbacp08323 Sample Peptide 4 from US011339203B2 FLLISACWVISLILGGLPIMGWKKRTLRKNDRKKR Synthetic Not Available CCK-8 assay CAKI-2 Renal Cancer Cell Viability = 85.6% at 25 μM
dbacp08324 Sample Peptide 5 from US011339203B2 LYHKHYILECTTVFTLLLLSIVILYCRIKKRTLRKNDRKKR Synthetic Not Available CCK-8 assay CAKI-2 Renal Cancer Cell Viability = 77.6% at 25 μM
dbacp08325 Sample Peptide 6 from US011339203B2 VIIVLSVFIACWAPLFILLLLKKRTLRKNDRKKR Synthetic Not Available CCK-8 assay CAKI-2 Renal Cancer Cell Viability = 59.7% at 25 μM
dbacp08326 Sample Peptide 7 from US011339203B2 LFRAEYFLVLAVLNSGTNPIIKKRTLRKNDRKKR Synthetic Not Available CCK-8 assay CAKI-2 Renal Cancer Cell Viability = 66.3% at 25 μM
dbacp08327 Sample Peptide 1 from EP3604345B1 MQIPQAPWPVVWAVLQLGWRKKRTLRKNDRKKR Synthetic Not Available CCK-8 / WST-8 NCI-H2444 Lung Cancer Cell Viability = 6.8% at 25 μM
dbacp08328 Sample Peptide 1 from EP3604345B1 MQIPQAPWPVVWAVLQLGWRKKRTLRKNDRKKR Synthetic Not Available CCK-8 / WST-8 HCC-827 Lung Cancer Cell Viability = 11.8% at 25 μM
dbacp08329 Sample Peptide 1 from EP3604345B1 MQIPQAPWPVVWAVLQLGWRKKRTLRKNDRKKR Synthetic Not Available CCK-8 / WST-8 NCI-H446 Lung Cancer Cell Viability = 0.5% at 25 μM
dbacp08330 Sample Peptide 1 from EP3604345B1 MQIPQAPWPVVWAVLQLGWRKKRTLRKNDRKKR Synthetic Not Available CCK-8 / WST-8 A-2058 Skin Cancer Cell Viability = 6.7% at 25 μM
dbacp08331 Sample Peptide 1 from EP3604345B1 MQIPQAPWPVVWAVLQLGWRKKRTLRKNDRKKR Synthetic Not Available CCK-8 / WST-8 MDA-MB-231 Breast Cancer Cell Viability = 62.3% at 25 μM
dbacp08332 Sample Peptide 2 from EP3604345B1 MQIPQAPWPVVWAVLQLGWRRKKRRQRRR Synthetic Not Available CCK-8 / WST-8 NCI-H2444 Lung Cancer Cell Viability = 3.6% at 25 μM
dbacp08333 Sample Peptide 2 from EP3604345B1 MQIPQAPWPVVWAVLQLGWRRKKRRQRRR Synthetic Not Available CCK-8 / WST-8 HCC-827 Lung Cancer Cell Viability = 4.9% at 25 μM
dbacp08334 Sample Peptide 2 from EP3604345B1 MQIPQAPWPVVWAVLQLGWRRKKRRQRRR Synthetic Not Available CCK-8 / WST-8 A-549 Lung Cancer Cell Viability = 9.1% at 25 μM
dbacp08335 Sample Peptide 3 from EP3604345B1 MRIFAVFIFMTYWHLLNAKKRTLRKNDRKKR Synthetic Not Available CCK-8 / WST-8 NCI-H2444 Lung Cancer Cell Viability = 87.7% at 25 μM
dbacp08336 Sample Peptide 3 from EP3604345B1 MRIFAVFIFMTYWHLLNAKKRTLRKNDRKKR Synthetic Not Available CCK-8 / WST-8 HCC-827 Lung Cancer Cell Viability = 120.6% at 25 μM
dbacp08337 Sample Peptide 3 from EP3604345B1 MRIFAVFIFMTYWHLLNAKKRTLRKNDRKKR Synthetic Not Available CCK-8 / WST-8 NCI-H446 Lung Cancer Cell Viability = 56.7% at 25 μM
dbacp08338 Sample Peptide 3 from EP3604345B1 MRIFAVFIFMTYWHLLNAKKRTLRKNDRKKR Synthetic Not Available CCK-8 / WST-8 A-2058 Skin Cancer Cell Viability = 87.5% at 25 μM
dbacp08339 Sample Peptide 3 from EP3604345B1 MRIFAVFIFMTYWHLLNAKKRTLRKNDRKKR Synthetic Not Available CCK-8 / WST-8 MDA-MB-231 Breast Cancer Cell Viability = 81.7% at 25 μM
dbacp08340 Sample Peptide 4 from EP3604345B1 PWWWPPVVVQQQMILLIGAARKKRTLRKNDRKKR Synthetic Not Available CCK-8 / WST-8 HCC-827 Lung Cancer Cell Viability = 102.6% at 25 μM
dbacp08341 Sample Peptide 5 from EP3604345B1 KKRTLRKNDRKKR Synthetic Not Available CCK-8 / WST-8 HCC-827 Lung Cancer Cell Viability = 106.5% at 25 μM
dbacp08342 VLL-28 VLLVTLTRLHQRGVIYEKWRHFSGRKYR Sulfolobus islandicus Not Available MTT assay HEK-293T Renal Cancer IC50 = 10 μM
dbacp08343 Phakellistatin 18 PIPYPIF Marine Sponge Phakellia fusca Not Available Cytotoxicity assay A-549 Lung Cancer IC50 = 72.42 µM
dbacp08344 Phakellistatin 18 PIPYPIF Marine Sponge Phakellia fusca Not Available Cytotoxicity assay BEL-7042 Cervical Cancer IC50 = 82.25 µM
dbacp08345 P18-1 PIPYPIF Analogue of Phakellistatin 18 Not Available Cytotoxicity assay A-549 Lung Cancer IC50 = 67.53 µM
dbacp08346 P18-1 PIPYPIF Analogue of Phakellistatin 18 Not Available Cytotoxicity assay BEL-7042 Cervical Cancer IC50 = 41.28 µM
dbacp08347 P18-2 PIPRPIF Analogue of Phakellistatin 18 Not Available Cytotoxicity assay A-549 Lung Cancer IC50 = 79.71 µM
dbacp08348 P18-2 PIPRPIF Analogue of Phakellistatin 18 Not Available Cytotoxicity assay BEL-7042 Cervical Cancer IC50 >100 µM
dbacp08349 LPSBD-0 CQYSVNPKIKRFELYFKGRMW Synthetic Not Available Not Available THP-1 Leukemia Cancer Not Available
dbacp08350 LPSBD-2 CHYRVKPKIKRFEKYKGRMW Synthetic Not Available Not Available THP-1 Leukemia Cancer Not Available
dbacp08351 Seq ID No. 15 from patent ID US202000079827A1 LKKWWKKVKGLLGGLLGKVTSVIK Synthetic Not Available Tetrazolium-based assay HOP-062 Lung Cancer Cell viability ~ 50% at 20 μM
dbacp08352 Seq ID No. 15 from patent ID US202000079827A1 LKKWWKKVKGLLGGLLGKVTSVIK Synthetic Not Available Tetrazolium-based assay NCI-H460 Lung Cancer Cell viability < 25% at 20 μM
dbacp08353 Seq ID No. 15 from patent ID US202000079827A1 LKKWWKKVKGLLGGLLGKVTSVIK Synthetic Not Available Tetrazolium-based assay Calu-1 Lung Cancer Cell viability < 50% at 20 μM
dbacp08354 Seq ID No. 16 from patent ID US202000079827A1 LKKWWKKVKGLLGGLLGKVKSVIK Synthetic Not Available Tetrazolium-based assay HOP-062 Lung Cancer Cell viability > 50% at 20 μM
dbacp08355 Seq ID No. 16 from patent ID US202000079827A1 LKKWWKKVKGLLGGLLGKVKSVIK Synthetic Not Available Tetrazolium-based assay NCI-H460 Lung Cancer Cell viability > 50% at 20 μM
dbacp08356 Seq ID No. 16 from patent ID US202000079827A1 LKKWWKKVKGLLGGLLGKVKSVIK Synthetic Not Available Tetrazolium-based assay Calu-1 Lung Cancer Cell viability > 50% at 20 μM
dbacp08357 Seq ID No. 17 from patent ID US202000079827A1 LKKWWKKVKGLLGGLLGKVKKVIK Synthetic Not Available Tetrazolium-based assay HOP-062 Lung Cancer Cell viability > 50% at 20 μM
dbacp08358 Seq ID No. 17 from patent ID US202000079827A1 LKKWWKKVKGLLGGLLGKVKKVIK Synthetic Not Available Tetrazolium-based assay NCI-H460 Lung Cancer Cell viability > 50% at 20 μM
dbacp08359 Seq ID No. 17 from patent ID US202000079827A1 LKKWWKKVKGLLGGLLGKVKKVIK Synthetic Not Available Tetrazolium-based assay Calu-1 Lung Cancer Cell viability > 50% at 20 μM
dbacp08360 Seq ID No. 26 from patent ID US202000079827A1 RRWVRRVRRVWRRVVRVVRRWVRR Synthetic Not Available Tetrazolium-based assay H-460 Lung Cancer Cell viability < 50% at 20 μM
dbacp08361 Seq ID No. 26 from patent ID US202000079827A1 RRWVRRVRRVWRRVVRVVRRWVRR Synthetic Not Available Tetrazolium-based assay Calu-1 Lung Cancer Cell viability > 50% at 20 μM
dbacp08362 Seq ID No. 34 from patent ID US202000079827A1 RRWvRRvRRvWRRvvRvvRRWvRR Synthetic Not Available Tetrazolium-based assay NCI-H460 Lung Cancer Cell viability < 25% at 20 μM
dbacp08363 Seq ID No. 34 from patent ID US202000079827A1 RRWvRRvRRvWRRvvRvvRRWvRR Synthetic Not Available Tetrazolium-based assay Calu-1 Lung Cancer Cell viability > 50% at 20 μM
dbacp08364 IDP-NS10 AALVVILKKATEYVHS Synthetic Not Available AlamarBlue assay RG1 Glioblastoma EC50 ~ 7 μM
dbacp08365 IDP-NS10 AALVVILKKATEYVHS Synthetic Not Available AlamarBlue assay GMB-27 Glioblastoma EC50 ~ 7.5 μM
dbacp08366 IDP-NS10 AALVVILKKATEYVHS Synthetic Not Available AlamarBlue assay 12015 Glioblastoma EC50 ~ 10 μM
dbacp08367 IDP-NS10 AALVVILKKATEYVHS Synthetic Not Available AlamarBlue assay 12089 Glioblastoma EC50 ~ 4 μM
dbacp08368 IDP-NS10 AALVVILKKATEYVHS Synthetic Not Available AlamarBlue assay RG6 Glioblastoma EC50 ~ 5 μM
dbacp08369 IDP-NS10 AALVVILKKATEYVHS Synthetic Not Available AlamarBlue assay RG4 Glioblastoma EC50 ~ 5 μM
dbacp08370 IDP-NS10 AALVVILKKATEYVHS Synthetic Not Available AlamarBlue assay RG5 Glioblastoma EC50 ~ 7 μM
dbacp08371 IDP-NS10 AALVVILKKATEYVHS Synthetic Not Available AlamarBlue assay 12053 Glioblastoma EC50 ~ 50 μM
dbacp08372 IDP-NS02 RQRRNDLRSSFLTLRDH Synthetic Not Available AlamarBlue assay NCI-H524 Lung Cancer EC50 ~ 5 μM
dbacp08373 IDP-NS16 RQRRNDLRSSFLTLRDH Synthetic Not Available AlamarBlue assay RG1 Glioblastoma EC50 ~ 15 μM
dbacp08374 IDP-NS16 RQRRNDLRSSFLTLRDH Synthetic Not Available AlamarBlue assay 12053 Glioblastoma EC50 ~ 10 μM
dbacp08375 IDP-Na05 RRNDLRSSFLTLRDHVP Synthetic Not Available AlamarBlue assay RG1 Glioblastoma EC50 ~ 10 μM
dbacp08376 IDP-NLCa02 RQIKIWFQNRRMKWKKRQRRNDLRSSFLTLRDHVP Synthetic Not Available AlamarBlue assay RG1 Glioblastoma EC50 ~ 5 μM
dbacp08377 IDP-wtL05 RKRRNDLRSRFLALRDQ Synthetic Not Available MTT/Alamamar-Blue/Hexosaminidase activity test RPMI Leukemia Cancer EC50 ~ 10 μM
dbacp08378 IDP-LS05 RKRRNDLRSRFLALRDQ Synthetic Not Available MTT/Alamamar-Blue/Hexosaminidase activity test HL-60 Leukemia Cancer EC50 ~ 5 μM
dbacp08379 IDP-LS05 RKRRNDLRSRFLALRDQ Synthetic Not Available MTT/Alamamar-Blue/Hexosaminidase activity test RPMI Leukemia Cancer EC50 ~ 6 μM
dbacp08380 IDP-LS13 RKRRNDLRSRFLALRDQ Synthetic Not Available MTT/Alamamar-Blue/Hexosaminidase activity test MCF-7 Breast Cancer EC50 ~ 10 μM
dbacp08381 IDP-LS13 RKRRNDLRSRFLALRDQ Synthetic Not Available MTT/Alamamar-Blue/Hexosaminidase activity test HL-60 Leukemia Cancer EC50 ~ 7 μM
dbacp08382 IDP-LS13 RKRRNDLRSRFLALRDQ Synthetic Not Available MTT/Alamamar-Blue/Hexosaminidase activity test RPMI Leukemia Cancer EC50 ~ 9 μM
dbacp08383 IDP-LS13 RKRRNDLRSRFLALRDQ Synthetic Not Available MTT/Alamamar-Blue/Hexosaminidase activity test U266 Lymphoma Cancer EC50 ~ 10 μM
dbacp08384 IDP-LS15 RKRRNDLRSRFLALRDQ Synthetic Not Available MTT/Alamamar-Blue/Hexosaminidase activity test RPMI Leukemia Cancer EC50 ~ 7 μM
dbacp08385 IDP-LS15 RKRRNDLRSRFLALRDQ Synthetic Not Available MTT/Alamamar-Blue/Hexosaminidase activity test U266 Lymphoma Cancer EC50 ~ 8 μM
dbacp08386 IDP-LS16 APKVVILSKALEYLQA Synthetic Not Available MTT/Alamamar-Blue/Hexosaminidase activity test RPMI Leukemia Cancer EC50 ~ 15 μM
dbacp08387 IDP-LS16 APKVVILSKALEYLQA Synthetic Not Available MTT/Alamamar-Blue/Hexosaminidase activity test U266 Lymphoma Cancer EC50 ~ 10 μM
dbacp08388 IDP-LS17 APKVVILSKALEYLQA Synthetic Not Available MTT/Alamamar-Blue/Hexosaminidase activity test RPMI Leukemia Cancer EC50 ~ 10 μM
dbacp08389 IDP-LS17 APKVVILSKALEYLQA Synthetic Not Available MTT/Alamamar-Blue/Hexosaminidase activity test U266 Lymphoma Cancer EC50 ~ 16 μM
dbacp08390 IDP-LLCb01 RRRRRRRSKAPKVVILSKALEYLQA Synthetic Not Available MTT/Alamamar-Blue/Hexosaminidase activity test NCl-H187 Lung Cancer EC50 ~ 5 μM
dbacp08391 IDP-LLCb01 RRRRRRRSKAPKVVILSKALEYLQA Synthetic Not Available MTT/Alamamar-Blue/Hexosaminidase activity test NCl-H82 Lung Cancer EC50 ~ 2.5 μM
dbacp08392 IDP-LLCb01 RRRRRRRSKAPKVVILSKALEYLQA Synthetic Not Available MTT/Alamamar-Blue/Hexosaminidase activity test NCl-H510A Lung Cancer EC50 ~ 5 μM
dbacp08393 IDP-LLCb02 RQIKWFQNRRMKWKKSKAPKVVILSKALEYLQA Synthetic Not Available MTT/Alamamar-Blue/Hexosaminidase activity test NCl-H187 Lung Cancer EC50 ~ 7.5 μM
dbacp08394 IDP-LLCb02 RQIKWFQNRRMKWKKSKAPKVVILSKALEYLQA Synthetic Not Available MTT/Alamamar-Blue/Hexosaminidase activity test NCl-H82 Lung Cancer EC50 ~ 10 μM
dbacp08395 IDP-LLCb02 RQIKWFQNRRMKWKKSKAPKVVILSKALEYLQA Synthetic Not Available MTT/Alamamar-Blue/Hexosaminidase activity test NCl-H510A Lung Cancer EC50 ~ 15 μM
dbacp08396 IDP-Lb01 SKAPKVVILSKALEYL Synthetic Not Available MTT/Alamamar-Blue/Hexosaminidase activity test NCl-H187 Lung Cancer EC50 ~ 22.5 μM
dbacp08397 IDP-Lb01 SKAPKVVILSKALEYL Synthetic Not Available MTT/Alamamar-Blue/Hexosaminidase activity test NCl-H82 Lung Cancer EC50 ~ 12.5 μM
dbacp08398 IDP-Lb01 SKAPKVVILSKALEYL Synthetic Not Available MTT/Alamamar-Blue/Hexosaminidase activity test NCl-H510A Lung Cancer EC50 ~ 22.5 μM
dbacp08399 IDP-Lb02 SKAPKVVILSKALEYL Synthetic Not Available MTT/Alamamar-Blue/Hexosaminidase activity test NCl-H187 Lung Cancer EC50 ~ 22.5 μM
dbacp08400 IDP-Lb02 SKAPKVVILSKALEYL Synthetic Not Available MTT/Alamamar-Blue/Hexosaminidase activity test NCl-H82 Lung Cancer EC50 ~ 7.5 μM
dbacp08401 IDP-Lb02 SKAPKVVILSKALEYL Synthetic Not Available MTT/Alamamar-Blue/Hexosaminidase activity test NCl-H510A Lung Cancer EC50 ~ 15 μM
dbacp08402 IDP-Lb03 SKAPKVVILSKALEYL Synthetic Not Available MTT/Alamamar-Blue/Hexosaminidase activity test NCl-H187 Lung Cancer EC50 ~ 22.5 μM
dbacp08403 IDP-Lb03 SKAPKVVILSKALEYL Synthetic Not Available MTT/Alamamar-Blue/Hexosaminidase activity test NCl-H82 Lung Cancer EC50 ~ 5 μM
dbacp08404 IDP-Lb03 SKAPKVVILSKALEYL Synthetic Not Available MTT/Alamamar-Blue/Hexosaminidase activity test NCl-H510A Lung Cancer EC50 ~ 15 μM
dbacp08405 IDP-Lb04 SKAPKVVILSKALEYL Synthetic Not Available MTT/Alamamar-Blue/Hexosaminidase activity test NCl-H187 Lung Cancer EC50 > 30 μM
dbacp08406 IDP-Lb04 SKAPKVVILSKALEYL Synthetic Not Available MTT/Alamamar-Blue/Hexosaminidase activity test NCl-H82 Lung Cancer EC50 ~ 12.5 μM
dbacp08407 IDP-Lb04 SKAPKVVILSKALEYL Synthetic Not Available MTT/Alamamar-Blue/Hexosaminidase activity test NCl-H510A Lung Cancer EC50 > 30 μM
dbacp08408 IDP-Lb05 SKAPKVVILSKALEYL Synthetic Not Available MTT/Alamamar-Blue/Hexosaminidase activity test NCl-H187 Lung Cancer EC50 ~ 10 μM
dbacp08409 IDP-Lb05 SKAPKVVILSKALEYL Synthetic Not Available MTT/Alamamar-Blue/Hexosaminidase activity test NCl-H82 Lung Cancer EC50 ~ 7.5 μM
dbacp08410 IDP-Lb05 SKAPKVVILSKALEYL Synthetic Not Available MTT/Alamamar-Blue/Hexosaminidase activity test NCl-H510A Lung Cancer EC50 ~ 12.5 μM
dbacp08411 IDP-Lb06 SKAPKVVILSKALEYL Synthetic Not Available MTT/Alamamar-Blue/Hexosaminidase activity test NCl-H187 Lung Cancer EC50 ~ 12.5 μM
dbacp08412 IDP-Lb06 SKAPKVVILSKALEYL Synthetic Not Available MTT/Alamamar-Blue/Hexosaminidase activity test NCl-H82 Lung Cancer EC50 ~ 7.5 μM
dbacp08413 IDP-Lb06 SKAPKVVILSKALEYL Synthetic Not Available MTT/Alamamar-Blue/Hexosaminidase activity test NCl-H510A Lung Cancer EC50 ~ 12.5 μM
dbacp08414 IDP-La05 RRNDLRSRFLALRDQVP Synthetic Not Available MTT/Alamamar-Blue/Hexosaminidase activity test NCl-H187 Lung Cancer EC50 ~ 22.5 μM
dbacp08415 IDP-La05 RRNDLRSRFLALRDQVP Synthetic Not Available MTT/Alamamar-Blue/Hexosaminidase activity test NCl-H82 Lung Cancer EC50 ~ 15 μM
dbacp08416 IDP-La05 RRNDLRSRFLALRDQVP Synthetic Not Available MTT/Alamamar-Blue/Hexosaminidase activity test NCl-H510A Lung Cancer EC50 ~ 10 μM
dbacp08417 5-2C NYPQRPCRGDKGPDC Synthetic Not Available MTT assay U343 Glioblastoma IC50 = 0.781 μM
dbacp08418 5-2C NYPQRPCRGDKGPDC Synthetic Not Available MTT assay U373MG Glioblastoma IC50 = 0.8717 μM
dbacp08419 5-2C NYPQRPCRGDKGPDC Synthetic Not Available MTT assay U251 Glioblastoma IC50 = 0.7607 μM
dbacp08420 5-2C NYPQRPCRGDKGPDC Synthetic Not Available MTT assay U87-MG Glioblastoma IC50 = 0.9164 μM
dbacp08421 5-2C NYPQRPCRGDKGPDC Synthetic Not Available MTT assay HepG-2 Liver Cancer IC50 = 3.064 μM
dbacp08422 5-2C NYPQRPCRGDKGPDC Synthetic Not Available MTT assay Hep3B Liver Cancer IC50 = 0.7847 μM
dbacp08423 5-2C NYPQRPCRGDKGPDC Synthetic Not Available MTT assay 293T Renal Cancer IC50 = 1.107 μM
dbacp08424 5-2C NYPQRPCRGDKGPDC Synthetic Not Available MTT assay MCF-7 Breast Cancer IC50 = 9.74 μM
dbacp08425 5-2C NYPQRPCRGDKGPDC Synthetic Not Available MTT assay MDA-MB-231 Breast Cancer IC50 = 0.8061 μM
dbacp08426 5-2C NYPQRPCRGDKGPDC Synthetic Not Available MTT assay HL-60 Blood Cancer IC50 = 1.111 μM
dbacp08427 5-2C NYPQRPCRGDKGPDC Synthetic Not Available MTT assay K-562 Blood Cancer IC50 = 1.103 μM
dbacp08428 5-2C NYPQRPCRGDKGPDC Synthetic Not Available MTT assay Hel Blood Cancer IC50 = 1.055 μM
dbacp08429 hBD3-3 M1 GKCSTRGRKCMRRKK Synthetic Not Available Cell Proliferation assay MDA-MB-231 Breast Cancer Concentration dependent reduction in colony formation between 100 μM and 200 μM.
dbacp08430 hBD3-3 M1 GKCSTRGRKCMRRKK Synthetic Not Available Annexin V/ PI staining assay MDA-MB-231 Breast Cancer Inhibition in growth by apoptosis as cells positive for annexin V formed 50% of test group
dbacp08431 hBD3-3 M2 GKCSTRGRKMCRRKK Synthetic Not Available Cell Proliferation assay MDA-MB-231 Breast Cancer Concentration dependent reduction in colony formation between 100 μM and 200 μM.
dbacp08432 hBD3-3 M2 GKCSTRGRKMCRRKK Synthetic Not Available Annexin V/ PI staining assay MDA-MB-231 Breast Cancer Inhibition in growth by apoptosis as cells positive for annexin V formed 50% of test group
dbacp08433 Alpha-gliadin peptide p31-43 LGQQQPFPPQQPY Synthetic Not Available MTT assay A-549 Lung Cancer 9.4% growth inhibition at 70 μg/mL
dbacp08434 Alpha-gliadin peptide p31-43 LGQQQPFPPQQPY Synthetic Not Available MTT assay NCI-H1975 Lung Cancer 36.3% growth inhibition at 70 μg/mL
dbacp08435 Alpha-gliadin peptide p31-43 LGQQQPFPPQQPY Synthetic Not Available MTT assay PANC-1 Pancreatic Cancer 26.2% growth inhibition at 70 μg/mL
dbacp08436 Alpha-gliadin peptide p31-43 LGQQQPFPPQQPY Synthetic Not Available TUNEL assay A-549 Lung Cancer Mean apoptotic rate = 36% at 200 μg/mL
dbacp08437 Balixafortide ACSAp(Dab)RYCYQKpPYH Synthetic Not Available HUVEC sprouting Namalwa Lymphoma IC50< 10 nM
dbacp08438 Balixafortide ACSAp(Dab)RYCYQKpPYH Synthetic Not Available HUVEC sprouting Jurkat Blood Cancer IC50< 10 nM
dbacp08439 Balixafortide ACSAp(Dab)RYCYQKpPYH Synthetic Not Available HUVEC sprouting MDA-MB-231 Breast Cancer IC50< 20 nM